Profiel
Brooks Rahmer is currently the Head-Investors Relations Contact at Rocket Pharmaceuticals, Inc. He previously worked as the Investor Relations Contact at MyoKardia, Inc. from 2019 to 2021.
Actieve functies van Brooks Rahmer
Bedrijven | Functie | Begin |
---|---|---|
ROCKET PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Eerdere bekende functies van Brooks Rahmer
Bedrijven | Functie | Einde |
---|---|---|
MYOKARDIA, INC. | Investor Relations Contact | 01-01-2021 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ROCKET PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |